CN102414212A - 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 - Google Patents
与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 Download PDFInfo
- Publication number
- CN102414212A CN102414212A CN2010800184448A CN201080018444A CN102414212A CN 102414212 A CN102414212 A CN 102414212A CN 2010800184448 A CN2010800184448 A CN 2010800184448A CN 201080018444 A CN201080018444 A CN 201080018444A CN 102414212 A CN102414212 A CN 102414212A
- Authority
- CN
- China
- Prior art keywords
- mmol
- cyclohexyl
- methoxy
- indolo
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CN(C)CC1(CC2)*2C*C1 Chemical compound CN(C)CC1(CC2)*2C*C1 0.000 description 10
- QWTZZAXPBKTYBQ-CABZTGNLSA-N COc(cc1)cc([C@H](C2)[C@]2(CO)C(O)=O)c1Br Chemical compound COc(cc1)cc([C@H](C2)[C@]2(CO)C(O)=O)c1Br QWTZZAXPBKTYBQ-CABZTGNLSA-N 0.000 description 2
- RRQITIHUHYCCJW-UHFFFAOYSA-N Bc(cc1)c(C=C)cc1OC Chemical compound Bc(cc1)c(C=C)cc1OC RRQITIHUHYCCJW-UHFFFAOYSA-N 0.000 description 1
- PJNPCKSPJXQBHH-UHFFFAOYSA-N CC(C)N(C)S(N)(=O)=O Chemical compound CC(C)N(C)S(N)(=O)=O PJNPCKSPJXQBHH-UHFFFAOYSA-N 0.000 description 1
- YWLMVVJLDHVRGZ-MIWMFXFDSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c([C@@H]3C4)cc2OC)[n]2C[C@]34C(N(C3)CC(C)(C4)C3(C)CN4C(OC)=O)=O)c2c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c([C@@H]3C4)cc2OC)[n]2C[C@]34C(N(C3)CC(C)(C4)C3(C)CN4C(OC)=O)=O)c2c1)=O)(=O)=O YWLMVVJLDHVRGZ-MIWMFXFDSA-N 0.000 description 1
- KKWNNKQYKAGZDB-UHFFFAOYSA-N CCCC(CC)c1c(-c(cc2)c(CC(C3)C(N4CC(CN(C)C5)(CN(C)C6)C56C4)=O)cc2OC)[n]3c2cc(C(NS(N(C)C)(=O)=O)=O)ccc12 Chemical compound CCCC(CC)c1c(-c(cc2)c(CC(C3)C(N4CC(CN(C)C5)(CN(C)C6)C56C4)=O)cc2OC)[n]3c2cc(C(NS(N(C)C)(=O)=O)=O)ccc12 KKWNNKQYKAGZDB-UHFFFAOYSA-N 0.000 description 1
- UVKDKNDVWUAHIF-XKDCNZLGSA-N CCCC(CCC)c1c(-c(cc2)c(C(C3)C3(C3)C(N[C@@H]4C(CC5)C(C)(C)C5(C)C4)=O)cc2OC)[n]3c2cc(C(NS(N(C)C)(=O)=O)=O)ccc12 Chemical compound CCCC(CCC)c1c(-c(cc2)c(C(C3)C3(C3)C(N[C@@H]4C(CC5)C(C)(C)C5(C)C4)=O)cc2OC)[n]3c2cc(C(NS(N(C)C)(=O)=O)=O)ccc12 UVKDKNDVWUAHIF-XKDCNZLGSA-N 0.000 description 1
- NSVGSFIKEXKUAM-MIWMFXFDSA-N CN(C)C(N1CC(CC2)(CN(C3)C([C@@](C4)(C[n]5c6c7)[C@@H]4c(cc(cc4)OC)c4-c5c(C4CCCCC4)c6ccc7C(NS(N(C)C)(=O)=O)=O)=O)C23C1)=O Chemical compound CN(C)C(N1CC(CC2)(CN(C3)C([C@@](C4)(C[n]5c6c7)[C@@H]4c(cc(cc4)OC)c4-c5c(C4CCCCC4)c6ccc7C(NS(N(C)C)(=O)=O)=O)=O)C23C1)=O NSVGSFIKEXKUAM-MIWMFXFDSA-N 0.000 description 1
- IZPUCLUAOJYRDR-UHFFFAOYSA-N CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(O)=O)c2c1)=O)(=O)=O Chemical compound CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(O)=O)c2c1)=O)(=O)=O IZPUCLUAOJYRDR-UHFFFAOYSA-N 0.000 description 1
- XKEROFYDQBTACD-JJNMFGATSA-N CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c([C@@H]3C4)cc2OC)[n]2C[C@]34C(N(C3)CC4(CN(CC(F)(F)F)C5)C35COC4)=O)c2c1)=O)(=O)=O Chemical compound CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c([C@@H]3C4)cc2OC)[n]2C[C@]34C(N(C3)CC4(CN(CC(F)(F)F)C5)C35COC4)=O)c2c1)=O)(=O)=O XKEROFYDQBTACD-JJNMFGATSA-N 0.000 description 1
- VROIPRWOKWXWHZ-JJNMFGATSA-N CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c([C@@H]3C4)cc2OC)[n]2C[C@]34C(N3CC(CC4)(CN(CC(F)(F)F)C5)C45C3)=O)c2c1)=O)(=O)=O Chemical compound CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c([C@@H]3C4)cc2OC)[n]2C[C@]34C(N3CC(CC4)(CN(CC(F)(F)F)C5)C45C3)=O)c2c1)=O)(=O)=O VROIPRWOKWXWHZ-JJNMFGATSA-N 0.000 description 1
- OSUUUKNLAJLMSQ-KYRSZARQSA-N COC(C(/C=C/c1ccccc1)=N)=O Chemical compound COC(C(/C=C/c1ccccc1)=N)=O OSUUUKNLAJLMSQ-KYRSZARQSA-N 0.000 description 1
- JOSGHYFFIDRFIE-DWWIYJRSSA-N COC([C@](C1)([C@@H]1c1cc(OC)ccc1Br)/C=C/c1ccccc1)=O Chemical compound COC([C@](C1)([C@@H]1c1cc(OC)ccc1Br)/C=C/c1ccccc1)=O JOSGHYFFIDRFIE-DWWIYJRSSA-N 0.000 description 1
- ZHWKEWKOYIOCAE-UHFFFAOYSA-N COc(cc1)cc(C=C(C[n]2c3c4)C(N(C5)CC6(CNC7)C57COC6)=O)c1-c2c(C1CCCCC1)c3ccc4C(NS(C1CC1)(=O)=O)=O Chemical compound COc(cc1)cc(C=C(C[n]2c3c4)C(N(C5)CC6(CNC7)C57COC6)=O)c1-c2c(C1CCCCC1)c3ccc4C(NS(C1CC1)(=O)=O)=O ZHWKEWKOYIOCAE-UHFFFAOYSA-N 0.000 description 1
- VYUVVDXLSGKNSV-LUFONEFESA-N C[C@H](/C(/C=C)=C/C)N Chemical compound C[C@H](/C(/C=C)=C/C)N VYUVVDXLSGKNSV-LUFONEFESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15563409P | 2009-02-26 | 2009-02-26 | |
| US61/155,634 | 2009-02-26 | ||
| PCT/US2010/025169 WO2010099159A1 (en) | 2009-02-26 | 2010-02-24 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102414212A true CN102414212A (zh) | 2012-04-11 |
Family
ID=42289577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800184448A Pending CN102414212A (zh) | 2009-02-26 | 2010-02-24 | 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8143244B2 (https=) |
| EP (1) | EP2401280B1 (https=) |
| JP (1) | JP2012519173A (https=) |
| CN (1) | CN102414212A (https=) |
| WO (1) | WO2010099159A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| JP2011515486A (ja) * | 2008-03-27 | 2011-05-19 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎の治療用化合物 |
| WO2009120890A1 (en) * | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors |
| US8119628B2 (en) * | 2008-03-27 | 2012-02-21 | Bristol-Myers Squibb Company | Pyrrolidine fused indolobenzadiazepine HCV NS5B inhibitors |
| LT3483164T (lt) | 2017-03-20 | 2020-05-11 | Forma Therapeutics, Inc. | Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| EP3853206B1 (en) | 2018-09-19 | 2024-04-10 | Novo Nordisk Health Care AG | Treating sickle cell disease with a pyruvate kinase r activating compound |
| HRP20251148T1 (hr) | 2019-09-19 | 2025-11-21 | Novo Nordisk Health Care Ag | Pripravci koji aktiviraju piruvat-kinazu r (pkr) |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| EP4269332A1 (de) | 2022-04-26 | 2023-11-01 | GasConTec GmbH | Verfahren und anlage zur herstellung von ammoniak |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101103026A (zh) * | 2005-01-14 | 2008-01-09 | 健亚生物科技公司 | 用于治疗病毒感染的吲哚衍生物 |
| WO2008097796A1 (en) * | 2007-02-02 | 2008-08-14 | Bristol-Myers Squibb Company | Indolobenzazepine derivatives for the treatment of hepatitis c |
| WO2008112848A1 (en) * | 2007-03-14 | 2008-09-18 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
| WO2008112841A1 (en) * | 2007-03-14 | 2008-09-18 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
| US20090042860A1 (en) * | 2007-08-09 | 2009-02-12 | Bristol-Myers Squibb Company | Compounds for the Treatment of Hepatitis C |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL161337A0 (en) * | 2001-10-26 | 2004-09-27 | Angeletti P Ist Richerche Bio | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| ATE355064T1 (de) * | 2001-10-26 | 2006-03-15 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| GB0201179D0 (en) | 2002-01-18 | 2002-03-06 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| EA009943B1 (ru) | 2002-11-01 | 2008-04-28 | Вирофарма Инкорпорейтед | Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита с, и связанных с ним заболеваний |
| US6745521B1 (en) * | 2002-12-13 | 2004-06-08 | Klemming Ulf Jp | Gazebo |
| NZ540729A (en) * | 2002-12-27 | 2008-03-28 | Angeletti P Ist Richerche Bio | Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors |
| WO2004062613A2 (en) * | 2003-01-13 | 2004-07-29 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| JP2004244320A (ja) | 2003-02-10 | 2004-09-02 | Shionogi & Co Ltd | 含窒素複素環抗ウイルス剤 |
| US7037908B2 (en) * | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| AR046938A1 (es) | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| CN1934093A (zh) | 2004-01-12 | 2007-03-21 | 吉里德科学公司 | 嘧啶基膦酸酯抗病毒化合物和使用方法 |
| PT1719773E (pt) | 2004-02-24 | 2009-06-03 | Japan Tobacco Inc | Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv |
| US7273859B2 (en) * | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| US7115601B2 (en) * | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7173022B2 (en) * | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7192948B2 (en) * | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7176196B2 (en) * | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7348425B2 (en) * | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| WO2006046039A2 (en) | 2004-10-26 | 2006-05-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
| CA2600832C (en) | 2005-03-31 | 2011-12-13 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hiv integrase inhibitors |
| WO2006121831A2 (en) | 2005-05-10 | 2006-11-16 | Merck & Co., Inc. | Hiv integrase inhibitors |
| EP1906971A2 (en) | 2005-07-27 | 2008-04-09 | Gilead Sciences, Inc. | Antiviral compounds |
| US7494984B2 (en) * | 2005-08-31 | 2009-02-24 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7897592B2 (en) * | 2005-11-15 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7902182B2 (en) * | 2005-11-16 | 2011-03-08 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8039458B2 (en) | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US20070129379A1 (en) * | 2005-12-01 | 2007-06-07 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) * | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7456167B2 (en) * | 2006-05-25 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521442B2 (en) * | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| WO2007143446A1 (en) * | 2006-05-30 | 2007-12-13 | Bristol-Myers Squibb Company | Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors |
| US7452876B2 (en) | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7893055B2 (en) * | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7541351B2 (en) * | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7517872B2 (en) * | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7998951B2 (en) * | 2007-03-05 | 2011-08-16 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| US7547690B2 (en) * | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7538102B2 (en) * | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7538103B2 (en) * | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US20090018163A1 (en) * | 2007-07-11 | 2009-01-15 | Bristol-Myers Squibb Company | Substituted Heterocyclic Ethers and Their Use in CNS Disorders |
| US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8129398B2 (en) * | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| JP2011515486A (ja) | 2008-03-27 | 2011-05-19 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎の治療用化合物 |
-
2010
- 2010-02-23 US US12/710,527 patent/US8143244B2/en active Active
- 2010-02-24 JP JP2011552097A patent/JP2012519173A/ja active Pending
- 2010-02-24 EP EP10722809.0A patent/EP2401280B1/en not_active Not-in-force
- 2010-02-24 CN CN2010800184448A patent/CN102414212A/zh active Pending
- 2010-02-24 WO PCT/US2010/025169 patent/WO2010099159A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101103026A (zh) * | 2005-01-14 | 2008-01-09 | 健亚生物科技公司 | 用于治疗病毒感染的吲哚衍生物 |
| WO2008097796A1 (en) * | 2007-02-02 | 2008-08-14 | Bristol-Myers Squibb Company | Indolobenzazepine derivatives for the treatment of hepatitis c |
| WO2008112848A1 (en) * | 2007-03-14 | 2008-09-18 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
| WO2008112841A1 (en) * | 2007-03-14 | 2008-09-18 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
| US20090042860A1 (en) * | 2007-08-09 | 2009-02-12 | Bristol-Myers Squibb Company | Compounds for the Treatment of Hepatitis C |
Non-Patent Citations (1)
| Title |
|---|
| VINCENZO SUMMA,等: "Discovery of a,γ-Diketo Acids as Potent Selective and Reversible Inhibitors of Hepatitis C Virus NS5b RNA-Dependent RNA Polymerase", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2401280B1 (en) | 2013-05-01 |
| WO2010099159A1 (en) | 2010-09-02 |
| EP2401280A1 (en) | 2012-01-04 |
| JP2012519173A (ja) | 2012-08-23 |
| US20100216774A1 (en) | 2010-08-26 |
| US8143244B2 (en) | 2012-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102414212A (zh) | 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 | |
| CN101490054B (zh) | 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 | |
| CN101631790B (zh) | 用于治疗丙型肝炎的化合物 | |
| US7521441B2 (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| CN101679441B (zh) | 用于治疗丙型肝炎的化合物 | |
| CN101679442B (zh) | 用于治疗丙型肝炎的化合物 | |
| CN101790533B (zh) | 环丙基稠合的吲哚并苯并氮杂*hcv抑制剂 | |
| CN101918410B (zh) | 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 | |
| CN101730698B (zh) | 用于治疗丙型肝炎的化合物 | |
| CN101821268B (zh) | 用于治疗丙型肝炎的四环化合物 | |
| CN101918412B (zh) | 用于治疗丙型肝炎的稠合有环丙基的吲哚并苯并氮杂*衍生物 | |
| KR20090008344A (ko) | 시클로프로필 융합된 인돌로벤즈아제핀 ｈｃｖ ｎｓ5ｂ 억제제 | |
| TW201014855A (en) | Compounds for the treatment of hepatitis C | |
| TW200848058A (en) | Compounds for the treatment of hepatitis C | |
| CN101679437B (zh) | 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 | |
| CN101646674B (zh) | 用于治疗丙型肝炎的吲哚并苯并氮杂*衍生物 | |
| CN101981038B (zh) | 二氧戊环和二氧戊环酮稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120411 |